ArticlePloS one2025
PIM1 induces hypoxia-related fibroblast senescence in a mouse model of stress urinary incontinence.
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- A Cell-Based Therapeutic Strategy for Stress Urinary Incontinence: Functional and Molecular Evidence from Decidua-Derived Mesenchymal Stromal Cells.International journal of molecular sciences · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThis study aims to explore the contribution of PIM1 kinase-mediated cellular senescence to the pathogenesis of stress urinary incontinence (SUI) and to assess the therapeutic potential of inhibiting PIM1.
methodsA mouse model of SUI was developed through vaginal balloon dilation to investigate hypoxia in the vaginal wall, utilizing HypoxyprobeTM-1 staining and HIF-1α expression analysis. Cellular senescence was evaluated by measuring SA-β-gal activity, senescence-associated heterochromatin foci (SAHF) formation, Ki67 expression, and γH2A.X accumulation. In vitro experiments involved the use of hypoxia-treated fibroblasts subjected to PIM1 knockdown or treatment with AZD-1208. Functional outcomes were assessed through bladder leak point pressure tests and histological analysis.
resultsThe study revealed that the SUI model exhibited significant reductions in vaginal wall blood flow and an increase in hypoxia markers. Indicators of cellular senescence were significantly elevated in SUI tissues, alongside a notable upregulation of PIM1. Mechanistically, PIM1 facilitated senescence through two pathways: inducing cell cycle arrest via activation of P16/P21 and impairing DNA repair through the formation of SAHF. Hypoxic conditions significantly enhanced PIM1 expression and senescence markers in fibroblasts, effects that were effectively reversed by PIM1 inhibition. Treatment with AZD-1208 led to significant improvements in bladder function and a reduction in senescence burden in vivo.
conclusionThis study identifies PIM1 as a critical mediator linking hypoxia-induced cellular senescence to the development of SUI. The PIM1 inhibitor AZD-1208 demonstrates promising therapeutic effects, offering a novel approach for the treatment of SUI, with particular relevance for postpartum prevention. These findings elucidate a comprehensive hypoxia-PIM1-senescence pathogenic pathway and identify a potential target for clinical intervention.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.